Mean (SE) SF-36 scores by treatment group: baseline and week 8
| SF-36 Domain | AbobotulinumtoxinA | Placebo | p Value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Baseline mean (SD) | Week 8 mean (SD) | Change mean (SD) | N | Baseline mean (SD) | Week 8 mean (SD) | Change mean (SD) | ||
| Physical Functioning* | 45 | 61.9 (20.0) | 70.1 (20.1) | 8.2 (16.0) | 37 | 68.2 (21.7) | 66.4 (23.4) | −1.9 (16.8) | 0.018 |
| Role Physical* | 44 | 46.3 (28.5) | 62.9 (25.1) | 16.6 (21.1) | 37 | 50.5 (29.9) | 53.7 (25.6) | 3.2 (24.0) | 0.008 |
| Bodily Pain* | 42 | 47.9 (23.0) | 61.8 (20.4) | 13.9 (19.7) | 37 | 49.0 (19.7) | 51.9 (22.0) | 2.9 (20.3) | 0.010 |
| General Health* | 44 | 58.9 (19.4) | 62.1 (18.4) | 3.2 (11.1) | 37 | 62.2 (19.6) | 59.7 (21.1) | −2.5 (10.6) | 0.030 |
| Vitality | 45 | 47.5 (15.6) | 56.0 (16.8) | 8.5 (15.0) | 37 | 50.5 (19.5) | 52.0 (19.2) | 1.5 (17.8) | 0.086 |
| Social Functioning | 43 | 62.2 (26.8) | 73.3 (22.9) | 11.0 (25.8) | 37 | 63.2 (25.0) | 67.2 (25.6) | 4.1 (15.6) | 0.125 |
| Role Emotional* | 44 | 71.0 (25.4) | 80.5 (21.5) | 9.5 (20.9) | 37 | 62.2 (28.0) | 66.4 (25.3) | 4.3 (26.8) | 0.030 |
| Mental Health | 45 | 62.6 (16.3) | 70.2 (15.8) | 7.7 (14.5) | 37 | 60.1 (20.9) | 63.9 (21.0) | 3.8 (15.2) | 0.125 |
Comparison between AbobotulinumtoxinA and placebo for change from baseline to week 8 using an ANCOVA model with baseline value as covariate.
*SF-36 domains that differed significantly (p<0.05) between abobotulinumtoxinA and placebo.
ANCOVA, analysis of covariance; SF-36, SF-36 Health Survey.